- Home
- QLGN vs PCSA Comparison
QLGN vs PCSA Comparison
Compare QLGN & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- PCSA
- Stock Information
- Founded
- QLGN 1996
- PCSA 2011
- Country
- QLGN United States
- PCSA United States
- Employees
- QLGN N/A
- PCSA N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- QLGN Health Care
- PCSA Health Care
- Exchange
- QLGN Nasdaq
- PCSA Nasdaq
- Market Cap
- QLGN 2.4M
- PCSA 2.8M
- IPO Year
- QLGN N/A
- PCSA N/A
- Fundamental
- Price
- QLGN $3.55
- PCSA $0.53
- Analyst Decision
- QLGN
- PCSA Strong Buy
- Analyst Count
- QLGN 0
- PCSA 2
- Target Price
- QLGN N/A
- PCSA $5.00
- AVG Volume (30 Days)
- QLGN 110.9K
- PCSA 508.0K
- Earning Date
- QLGN 04-07-2025
- PCSA 03-28-2025
- Dividend Yield
- QLGN N/A
- PCSA N/A
- EPS Growth
- QLGN N/A
- PCSA N/A
- EPS
- QLGN N/A
- PCSA N/A
- Revenue
- QLGN N/A
- PCSA N/A
- Revenue This Year
- QLGN N/A
- PCSA N/A
- Revenue Next Year
- QLGN N/A
- PCSA N/A
- P/E Ratio
- QLGN N/A
- PCSA N/A
- Revenue Growth
- QLGN N/A
- PCSA N/A
- 52 Week Low
- QLGN $2.96
- PCSA $0.47
- 52 Week High
- QLGN $29.45
- PCSA $3.31
- Technical
- Relative Strength Index (RSI)
- QLGN 47.06
- PCSA 30.16
- Support Level
- QLGN $3.16
- PCSA $0.58
- Resistance Level
- QLGN $3.75
- PCSA $0.71
- Average True Range (ATR)
- QLGN 0.21
- PCSA 0.06
- MACD
- QLGN 0.06
- PCSA 0.00
- Stochastic Oscillator
- QLGN 67.25
- PCSA 0.00
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).